Article type
Abstract
Background: Some research reports show that statins have anti-inflammatory effects. However, the results of clinical trials on the effects of statins on the level of high-sensitivity C-reactive protein (hs-CRP) are inconsistent. Therefore, we systematically evaluated the randomized clinical trials to evaluate the effect of statins on the level of hs-CRP in patients with cardiovascular diseases, and conducted a network meta-analysis to evaluate the evidence of statins on the level of serum hs-CRP in patients with cardiovascular diseases.
Objective: To evaluate the evidence that statins affect serum hs-CRP levels in patients with cardiovascular disease.
Methods: Randomized controlled trials (RCTs) involving the effects of statins on hs-CRP levels were screened from seven databases (March 2023). STATA15.1 software was used for network meta-analysis. Bias risk was assessed using the Cochrane Bias Risk tool.
Results: A total of 19 randomized controlled trials involving 5152 patients with cardiovascular disease were included, one study was rated as having a low risk of bias. All trials reported six interventions and the results were compared 15 times. Network meta-analysis showed that simvastatin showed a significant advantage, Simvastatin (MD = 7.16; 95% CI [2.30,12.01]) had a significant advantage over placebo. In addition, simvastatin (MD = 6.77; 95% CI [1.62,11.91]; MD = 10.07; 95% CI [2.94,17.21]; MD = 8.41; 95% CI [2.82,13.99]) was superior to rosuvastatin, fluvastatin and atorvastatin. The cumulative ranking curve values showed that Simvastatin (SUCRA = 99.1%) had the highest probability of being the best intervention, followed by Rosuvastatin (SUCRA = 58.8%).
Conclusions: Simvastatin has a significant advantage over placebo, showing the strongest efficacy in all probability ranking charts.
Objective: To evaluate the evidence that statins affect serum hs-CRP levels in patients with cardiovascular disease.
Methods: Randomized controlled trials (RCTs) involving the effects of statins on hs-CRP levels were screened from seven databases (March 2023). STATA15.1 software was used for network meta-analysis. Bias risk was assessed using the Cochrane Bias Risk tool.
Results: A total of 19 randomized controlled trials involving 5152 patients with cardiovascular disease were included, one study was rated as having a low risk of bias. All trials reported six interventions and the results were compared 15 times. Network meta-analysis showed that simvastatin showed a significant advantage, Simvastatin (MD = 7.16; 95% CI [2.30,12.01]) had a significant advantage over placebo. In addition, simvastatin (MD = 6.77; 95% CI [1.62,11.91]; MD = 10.07; 95% CI [2.94,17.21]; MD = 8.41; 95% CI [2.82,13.99]) was superior to rosuvastatin, fluvastatin and atorvastatin. The cumulative ranking curve values showed that Simvastatin (SUCRA = 99.1%) had the highest probability of being the best intervention, followed by Rosuvastatin (SUCRA = 58.8%).
Conclusions: Simvastatin has a significant advantage over placebo, showing the strongest efficacy in all probability ranking charts.